Key words: anticoagulation; clinical trial; dermatan sulphate; haemodialysis; heparin Background. Dermatan sulphate (DS ) is a selective thrombin inhibitor with antithrombotic properties and low bleeding potential. In preliminary studies it was reported to be effective for preventing clot formation Introduction in the haemodialysis circuit.
capacity was expressed as percentage of the nominal capacity procedure [14] [15] [16] [17] . It also induced a moderate prospecified by the manufacturer. The dialysate compartment longation of activated partial thromboplastin time was kept full during the procedure.
( APTT ) [15] [16] [17] . These effects were related to dermatan sulphate doses and plasma concentrations, which followed linear pharmacokinetics [15] [16] [17] . Effective Study design. Criteria for clinical efficacy and safety doses ranged from 6 to 10 mg/kg body weight per Each patient underwent three consecutive investigation dialysis session, depending on the type of dialyser and phases. In phase 1 (individual dose titration), repeated duration of the procedure [14] [15] [16] [17] [18] . dialyses were performed with dermatan sulphate until As an extension of the above experience, the present successful dialysis was obtained in two consecutive sessions study was aimed at: (i) finding the lowest effective at the same dose. The starting dose was 4 mg/kg as a bolus individual dose of dermatan sulphate for haemodialysis and 0.65 mg/kg/h as an infusion. In case of failure, the dose in each of 10 uraemic patients; (ii ) validating the was increased stepwise to 5 mg/kg plus 0.65 mg/kg/h, individualized doses by comparison with the individu-5 mg/kg plus 1 mg/kg/h, and 5 mg/kg plus 1.3 mg/kg/h. alized heparin regimens currently used in the same Successful dialysis was defined as regular completion of the patients; (iii) assessing the continued efficacy and safety procedure without visible clot formation in the bubble traps and lines or >20% decrease in dialyser capacity as an index of dermatan sulphate over a period of 8 weeks.
of fibrin deposition. Pre-to post-dialysis changes in serum urea and creatinine were also assessed.
Subjects and methods
Phase 2 was a randomized crossover comparison of two consecutive dialysis sessions, using the dermatan sulphate dose established in phase 1 and the patient's individual Patients heparin dose as established before the study. Anticoagulation efficacy was assessed according to residual dialyser capacity, Patients with chronic renal failure, undergoing maintenance changes in serum urea and creatinine, and post-dialysis ratio haemodialysis at the Nephrology and Dialysis Division of of total clearance to distribution volume of urea ( Kt/V, Ospedali Riuniti, Bergamo, were eligible for the study if calculated according to Daugirdas [20 ] ). Laboratory personmeeting the following criteria: age Á18 years; dialysis nel were blind to treatment allocation. frequency, three times a week; haematocrit between 25 and
In phase 3, patients underwent 24 consecutive dialyses 32%; blood flow in the extracorporeal circuit Á200 ml/min; with dermatan sulphate over a period of 8 weeks. Residual no recent or current history of cardiac or cerebral ischaemia, dialyser capacity was assessed for each dialysis; changes in uncontrolled arterial hypertension, symptomatic hyposerum urea and creatinine and Kt/V were determined on the tension, intradialytic blood transfusions, or pregnancy; no first and last sessions. current treatment with drugs known to affect haemostasis.
Patients were followed for adverse clinical events over the Written informed consent was obtained in each case. Ethical study period. Haemoglobin, haematocrit, leukocyte and and administrative approvals were obtained from the platelet count, ALT, and AST were also monitored. Commissione Consultiva per la Sperimentazione Clinica, Regione Lombardia, and Direzione Sanitaria, Ospedali Riuniti, Bergamo.
Effects on haemostatic function and pharmacokinetics
Phase 1: APTT was determined immediately before dialysis, Anticoagulation and dialysis procedure 1, 2 and 3 h from its onset and at dialysis end (if longer than 3 h), using IL-Test liophilized silica reagent (Instrumentation Dermatan sulphate (MF701, 200 mg/2 ml ampoules, Mediolanum Farmaceutici, Milan, Italy) was injected intra-Laboratory) and expressing the result as ratio to control plasma. venously by an electrical pump as a slow bolus (2 min) immediately before dialysis onset, followed by a constant Phase 2: APTT and plasma concentration of fibrinopeptide A (FpA), a marker of fibrin generation, were determined at rate infusion interrupted 30 min before dialysis end. Sodium heparin ( Eparina Vister, 5000 IU/ml multi-dose vials, the above time-points. On the heparin session, the relevant blood samples were taken immediately before heparin injecParke-Davis, Lainate, Italy) was administered by repeated intravenous bolus injections [19] . An individually adjusted tions. FpA was assayed on frozen plasma at Istituto Mario Negri, Bergamo, using a radioimmunoassay kit ( Bykpre-dialysis dose was followed by 60% of the same dose at 1 h, 60% at 2 h and, if dialysis lasted longer than 3.5 h, 40% Sangtec, Diagnostica GmbH ), after addition of bentonite to remove potentially cross-reactive fibrinogen and fibrinogen at 3 h. Before dialysis the circuit was primed with dermatan sulphate, 300 mg/l saline, or with heparin, 5000 IU/l saline. degradation products. Ex vivo platelet adhesion from whole blood to collagen-coated surfaces under flowing conditions Patients were dialysed over 3-4 h on a parallel-flow kidney with cellulosic membrane (CA210, Baxter Renal Division). was tested on a sample taken 15 min from dialysis onset, according to the method of Aleviadrou et al.
[ 21] modified Extracorporeal blood flow was maintained between 250 and 300 ml/min. Dialysate flow was 500 ml/min. The dialysate as follows. A flow chamber thermostatized to 37°C was used, in which one surface of the perfusion channel was a glass formula was kept unchanged throughout the study. On each session, the bubble traps and lines were visually inspected slide coated with collagen for aggregation. The system was perfused with TRIS buffer (pH 7.3) for 1 min, then with for clot formation at hourly intervals. At the session end, the blood compartment of the dialyser was washed with the test blood without added anticoagulant for 2 min.
The shear rate was 1500 s−1. Platelet thrombi adherent to saline through the arterial line. The arterial and venous lines were clamped before disconnecting the dialyser. The venous the collagen-coated slide were fixed and stained with May-Grunwald-Giemsa. Platelet adhesion was assessed at line clamp was then removed and the volume of effluent saline was measured. A manual pump was used to ensure Istituto Mario Negri with a computer image analysis system connected to a video camera and a light-microscope, and complete emptying of the blood compartment. Dialyser expressed as percentage of the surface covered by thrombi. and to 2.4 at the session end (2.3-2.6 and 2.1 respectTen microscope fields per slide were measured using system-ively, in the second session). atic sampling. Bleeding time was measured pre-and immediately postdialysis as average from two forearm skin incisions,
Phase 2
using Simplate II device (General Diagnostic) under a counterpressure of 40 mmHg. The reference range was 180-420 Individual dialysis time (mean 3.7 h) was the same for s. Dermatan sulphate plasma concentration was monitored both sessions. Using regimens established in phase 1, on the session performed with this agent. The relevant assays the total per dialysis dose of dermatan sulphate was were performed on frozen plasma in the Mediolanum between 5.6 and 6.3 mg/kg in nine patients and investigated variables. No statistically significant Phase 3: APTT was monitored on the first and last dialysis differences were found between dermatan sulphate and sessions. Pre-dialysis dermatan sulphate plasma concentra-heparin in any of the investigated variables. Residual tion was determined on sessions 1, 9, 18 and 24.
dialyser capacity, urea and creatinine decreases and Kt/V obtained with dermatan sulphate and heparin indicated equivalent efficacy within narrow confidence Statistical analysis limits ( Table 1) . AUCs of plasma FpA levels were also Areas under the curves (AUC ) of APTT ratio and FpA compatible with equivalence although with a much levels over dialysis time were calculated by the trapezoidal wider confidence interval, due to the large inter-patient rule. Data from successful dialyses of phase 1 and from first variability observed with both drugs (Table 1 ) .
and last sessions of phase 3 were summarized by descriptive
The time course of APTT ratio is shown in Figure 1 . statistics. Analysis of variance for crossover designs was The resulting AUCs, reported in Table 1 , showed a applied on data from phase 2, including treatment, carry-smaller coefficient of variation with dermatan sulphate over and period effects in the model. Analysis of AUCs of (26.2%) than with heparin (44.2%). Ex vivo platelet FpA was conducted on log-transformed values to obtain adhesion to collagen was almost identical with either homogeneous variances. Significance level was set at 0.05 treatment ( Table 1 ) . Three patients had a pre-dialysis (two-sided ). 95% confidence intervals were calculated for the bleeding time >420 s on both sessions. Post-dialysis estimated differences between dermatan sulphate and heparin. Statistical analysis was performed with SAS pack-changes (n=8; a reliable measurement could not be age, version 6.10 (SAS Institute, Cary, NC, USA). Unless obtained in two patients) are reported in Table 1 . Mean otherwise specified, data are reported as mean (SD).
dermatan sulphate plasma concentrations ( Figure 1 ) showed a minor peak at 15 min (41 mg/ml ) as a result
Results
Ten patients (4 females) were included in the study. The age range was 46-78 years (mean 65.5) and body weight 49-102 kg (mean 66.7). They had been on maintenance haemodialysis for 1.5-84 months (median 15 months). Chronic renal failure was due to polycystic kidney disease in two patients, lupus nephritis in one, and to unknown causes in seven. Three patients were on chronic treatment with recombinant erythropoietin. One patient had chronic thrombocytopenia. All patients completed the three investigation phases. A total of 275 dialysis sessions were investigated ( 23 in phase 1, 20 in phase 2 and 232 in phase 3).
Phase 1
Successful dialysis was achieved in nine patients with the starting dose of dermatan sulphate (4 mg/kg plus 0.65 mg/kg/h), while the remaining patient required 5 mg/kg plus 1.3 mg/kg/h. After the first and second sessions performed with the effective dose, residual dialyser capacity was 90.4 (4.4)% and 90.0 (4.1)% of the nominal value. Pre-to post-dialysis decrease in of the initial bolus injection and then stabilized around Safety 30 mg/ml. No bleeding episode was observed in any investigation phase, nor other clinically overt adverse reactions.
Phase 3
Mean predialysis haematology and liver enzyme data remained stable over the study period, and the corresOne patient was switched from thrice-to twice-weekly ponding mean postdialysis changes were minimal with dialysis when beginning phase 3. The same dialysis either treatment. Individual data showed a drop in time and dermatan sulphate dose used in phase 2 were platelet count (104 to 51×109/l ) in one patient after maintained for each patient. Residual dialyser capacity heparin dialysis in phase 2. In the patient with chronic after the initial and final sessions was unchanged, as thrombocytopenia, platelet count over the study period shown in Table 2 . On the intervening 22 dialyses, mean fluctuated between 40 and 100×109/l and did not capacity never dropped below 86%, the relevant SD decrease with time. never exceeding 5%. Urea and creatinine changes and Kt/V also remained stable over the 8-week period ( Table 2 ). Some decrease in APTT response to dermatan sulphate (n=8) was apparent in the final session Discussion ( Table 2 ) . Predialysis bleeding time (n=9) was 431 ( 48) and 417 (62) s on the initial and final sessions It is well known that heparin requirement for haemorespectively. The corresponding postdialysis changes dialyis varies according to dialysis technique, are shown in Table 2 .
membrane type, and individual patient characteristics. In two patients, residual dermatan sulphate was Inter-patient variability was also suggested by earlier repeatedly detected in plasma before dialyses 9, 18 and dialysis studies using fixed doses of dermatan sulphate 24. Drug concentrations ( 1.3-2.7 mg/ml ) were low as [14] [15] [16] [17] [18] . With this background, an individual dose compared with on-dialysis levels and did not increase titration approach was chosen for the present study, with time. Four additional patients had residual drug based on a simple assessment of clot formation in the levels before dialyses 1 (carried over from phase 2 ) or dialysis circuit. Dermatan sulphate regimens were mod-9 or 18 (1.1-3.9 mg/ml ), which, however, disappeared elled from available pharmacokinetic and clinical data before dialysis 24. Predialysis APTT of the patients [15] [16] [17] [18] . The aim was to keep potentially effective with measurable drug levels was ∏1.0.
plasma drug concentrations as steady as possible over the procedure, thereby minimizing total dose requirement. A combination of bolus injection and continuous infusion was therefore adopted. (10) 18 ( 18) levels was successfully achieved, as shown in Table 2 .
The titrated doses were then tested for efficacy over single dialyses against the current heparin regimen of Data are expressed as mean (SD). *Pre-to post-dialysis change.
each patient, and for consistency of effect in pro-tan sulphate regimen maintains its anticoagulant efficacy and is safe in prolonged use. longed use.
Equal anticoagulant efficacy was shown for dermaThese findings confirm that dermatan sulphate is a suitable alternative to heparin for anticogulation in tan sulphate and heparin on clot formation in the dialyser, as reflected by dialyser capacity, and on the haemodialysis. Dermatan sulphate has pharmacological advantages with potential relevance to dose-resresulting overall efficiency of dialysis, as reflected by urea and creatinine changes and Kt/V. FpA genera-ponse predictability and to the risk of bleeding, thrombocytopenia and osteoporosis. Long-term comtion, reflecting systemic activation of the coagulation system, was extremely variable without any detectable parative trials are warranted to assess whether these translate into significant clinical benefits for uraemic trend in favour of either drug. APTT response to dermatan sulphate was less variable than to heparin, patients on maintenance haemodialysis. consistently with the narrower dose range of the former drug, but it was not significantly reduced as found Acknowledgements. We wish to thank Dr Giuseppe Remuzzi for his continuing support and advice on the manuscript, Dr Miriam in earlier comparative studies [15] [16] [17] . Two likely Galbusera for her helpful scientific contribution and Dr Anna Chiara explanations are that present heparin doses were Frigo for data handling and statistical analysis. The study was slightly lower than in previous studies and that the supported in part by a grant from Mediolanum Farmaceutici, AUC of APTT with heparin was underestimated, as Milan, Italy. peaks following repeated bolus injections could not be detected with pre-injection blood sampling.
As concerns primary haemostasis, neither dermatan References sulphate nor heparin produced a clear-cut change in
